3.5.2.B2: (+)-gamma-lactamase
This is an abbreviated version!
For detailed information about (+)-gamma-lactamase, go to the full flat file.
Word Map on EC 3.5.2.B2
-
3.5.2.B2
-
drug development
-
synthesis
-
abacavir
-
enantioselective
-
sulfolobus
-
microbacterium
-
carbovir
-
biuret
-
racemic
-
enantiomeric
-
solfataricus
-
carbocyclic
-
nucleoside
-
japonicum
-
bradyrhizobium
-
industry
- 3.5.2.B2
- drug development
- synthesis
- abacavir
-
enantioselective
-
sulfolobus
-
microbacterium
-
carbovir
- biuret
-
racemic
-
enantiomeric
- solfataricus
-
carbocyclic
- nucleoside
- japonicum
-
bradyrhizobium
- industry
Reaction
Synonyms
(+) gamma-lactamase, (+)-gamma-lactamase, BJ6T_02120, Daci_0225, Delm, FDB1, FGSG_00079, FPSE_08124, IHL, isochorismatase-like hydrolase, Mh33H4-5540, MhIHL, Mhpg, RutB, Sslact, SSO2810, Sspg, SYJ322B5
ECTree
Advanced search results
Application
Application on EC 3.5.2.B2 - (+)-gamma-lactamase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
industry
the enzyme can be a promising candidate of biocatalyst for industrial applications of highly valuable chiral pharmaceutical chemicals
synthesis
application of the enzyme in antiviral drug synthesis. The enzyme catalyzes the specific hydrolysis of (+)-gamma-lactam out of the racemic gamma-lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) to leave optically pure (-)-gamma-lactam, which is the key building block of antiviral drugs such as carbovir and abacavir
drug development
the enzyme can be a promising candidate of biocatalyst for industrial applications of highly valuable chiral pharmaceutical chemicals
drug development
the enzyme is an ideal catalyst for the preparation of carbocyclic nucleosides of pharmaceutical interest. IT can be used in a scalable bioprocess and is an efficient, economical, and environmentally route for producing optically pure (-)-gamma-lactam
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
drug development
Pseudomonas fluorescens ENZA 22
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
drug development
Ralstonia solanacearum ENZA 20
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
drug development
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
drug development
-
the enzyme is an ideal catalyst for the preparation of carbocyclic nucleosides of pharmaceutical interest. IT can be used in a scalable bioprocess and is an efficient, economical, and environmentally route for producing optically pure (-)-gamma-lactam
-
drug development
Delftia sp. CGMCC 5755
-
the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
-
enantioselective resolution of 100 g/l 2-azabicyclo[2.2.1]hept-5-en-3-one, is achieved with 10 g/l dry cells, resulting in 55.2% conversion and 99% enantiomeric excess of the (-)-gamma-lactam, i.e. (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one
synthesis
-
the enantiomers of substrate 2-azabicyclo[2.2.1]hept-5-en-3-one (gamma-lactam) are key chiral synthons in the synthesis of antiviral drugs such as carbovir and abacavir
synthesis
(+)-gamma-lactamase catalyzes the specific hydrolysis of (+)-gamma-lactam out of the racemic gamma-lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) to leave optically pure (-)-gamma-lactam, which is the key building block of antiviral drugs such as carbovir and abacavir
synthesis
mutant enzyme Q192S/L223Y can be employed for the preparation of (-)-gamma-lactam and also for that of (2S,3R)-ethyl 3-phenylglycidate
synthesis
the enzyme may become a potential tool for the production of (-)-gamma-lactam because of its superior physicochemical properties and high enzyme activity
synthesis
A0A5E8GM52
the transformation of an active but unstable mesophilic enzyme into a stable catalyst, achieved by immobilizing the enzyme on macroporous resins, provides a feasible approach for the preparation of optically active (-)-Vince lactam (i.e. 2-azabicyclo [2.2.1] hept-5-en-3-one), which is an important chiral synthon used as an intermediate in organic chemistry
synthesis
-
enantioselective resolution of 100 g/l 2-azabicyclo[2.2.1]hept-5-en-3-one, is achieved with 10 g/l dry cells, resulting in 55.2% conversion and 99% enantiomeric excess of the (-)-gamma-lactam, i.e. (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one
-
synthesis
-
the enantiomers of substrate 2-azabicyclo[2.2.1]hept-5-en-3-one (gamma-lactam) are key chiral synthons in the synthesis of antiviral drugs such as carbovir and abacavir
-
synthesis
-
the transformation of an active but unstable mesophilic enzyme into a stable catalyst, achieved by immobilizing the enzyme on macroporous resins, provides a feasible approach for the preparation of optically active (-)-Vince lactam (i.e. 2-azabicyclo [2.2.1] hept-5-en-3-one), which is an important chiral synthon used as an intermediate in organic chemistry
-
synthesis
-
mutant enzyme Q192S/L223Y can be employed for the preparation of (-)-gamma-lactam and also for that of (2S,3R)-ethyl 3-phenylglycidate
-